Cardiovascular Systems Unveils Late-Breaking Confirmation Series Data at ISET Conference
Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), will present late-breaking data from its CONFIRM study series, an oral abstract from its CALCIUM study, and conduct other educational and poster sessions at the 25^th annual International Symposium on Endovascular Therapy (ISET) conference in Miami, Jan. 19–23, 2013.
The CONFIRM study series evaluated the safety and procedural effectiveness of CSI's orbital atherectomy system as a treatment for peripheral arterial disease (PAD) —above- and below-the-knee lesions— in a real world population of patients (no exclusions). Eighty-one percent of the lesions had severe or moderate calcification—historically considered a difficult patient population to treat. CONFIRM, like other studies in CSI's growing body of clinical research, is aimed at providing physicians with scientific data to make sound treatment decisions.
Arterial calcification is a common, underdiagnosed condition with complicating factors—including a higher frequency of dissections and perforations—that pose a challenge for physicians treating PAD. Calcified lesions are estimated to be present in approximately 65 percent of the people treated annually for PAD and are more prevalent in distal vessels below the knee.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.